Overview Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) Status: Completed Trial end date: 2006-01-01 Target enrollment: Participant gender: Summary An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.